Mineralocorticoid receptor (MR) antagonists are the recommended medical therapy for primary aldosteronism. Whether this recommendation effectively reduces cardiometabolic risk is not well understood. We aimed to investigate the risk of incident cardiovascular events in patients with primary aldosteronism treated with MR antagonists compared with patients with essential hypertension.

中文翻译：

---

药物治疗的原发性醛固酮增多症的心脏代谢结果和死亡率：一项回顾性队列研究。

盐皮质激素受体 (MR) 拮抗剂是原发性醛固酮增多症的推荐药物治疗。这一建议是否能有效降低心脏代谢风险尚不清楚。我们的目的是调查与原发性高血压患者相比，接受 MR 拮抗剂治疗的原发性醛固酮增多症患者发生心血管事件的风险。